InterCure Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
InterCure Ltd. - overview
Established
1994
Location
-, -, Israel
Primary Industry
Medical Devices & Equipment
About
Founded in 1994 and based in HaMerkaz, Israel, InterCure, Inc. is both a medical device and cannabis company. In February 2021, InterCure Ltd. raised USD 8 million in private investment in public equity funding led by new investor ARK Investment Management and in April 2021, SUBVERSIVE ACQUISITION LP merged with InterCure Ltd.
The company’s chairman is former Israeli prime minister Ehud Barak and its CEO is Alexander Rabinovitch. The Company operates a marketing office in London and outsourced call centers and warehouses in the United States, the United Kingdom, Germany and Canada. InterCure, Inc. started as a developer of RESPeRATE, a non-invasive and respiratory-based medical device used to treat hypertension but later added cannabis to its product line after acquiring Canndoc, a producer and developer of medical cannabis products in 2018.
RESPeRATE is a U. S. Food and Drug Administration approved non-drug hypertension treatment device clinically proven to lower high blood pressure and is marketed in the USA, Europe and other key markets. The machine uses chest sensors to measure user’s breathing, and then sends the real-time information to a small device they wear as a belt that creates a melody for them to listen to and synchronize their breathing.
The melody helps users to perform slow breathing with long exhalations. InterCure, Inc. also provides good manufacturing practices certified and pharmaceutical-grade medical cannabis products through its market distribution network formed by international partnerships and a high-margin vertically integrated seed-to-sale model. In 2020, the company generated a revenue of USD 65.
04 million with a sales growth of 628. 60% resulting in a growth income of USD 29. 64 million along with an EBITDA of USD 5. 02 million.
In December 2024, InterCure Ltd. raised USD 29. 8 million in venture funding from Individual investors. The company plans to list its shares on NASDAQ in 2021 under the Symbol of INCR.
The company will use the funding to support the recovery of Nir Oz Facility.
Current Investors
GMF Capital Partners, Paladin Capital Group, True North Venture Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Alternative Medicine, Therapeutic Devices
Website
www.intercure.co
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
InterCure Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | InterCure Ltd. | - | ||||||||
| Unspecified Exit | Completed | InterCure Ltd. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.